Trial
NCT03445000
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
ETOP IBCSG Partners Foundation
Collaborators
Hoffmann-La Roche
Condition
Non-small Cell Lung Cancer
Intervention
Alectinib
Why stopped
Low recruitment rate
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-21